# Greenwich LifeSciences, Inc.: Form 10-Q for the period ended Jun 30, 2021 - Company: [Greenwich LifeSciences, Inc.](/companies/glsi.md) (CIK 1799788) - Form: 10-Q - Filed: 2021-08-13 - Accepted by EDGAR: Aug 13, 2021, 16:16 ET - Period: 2021-06-30 - Accession: 0001493152-21-019718 - Inline XBRL: yes - Main document: https://www.sec.gov/Archives/edgar/data/1799788/000149315221019718/form10-q.htm - All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1799788/000149315221019718/ ## Figures reported in this filing Standardized XBRL line items for the period ended 2021-06-30. | Line item | Period | Value | XBRL concept | | --- | --- | ---: | --- | | Research and development | 3 months, 2021-04-01 to 2021-06-30 | $556.5k | us-gaap:ResearchAndDevelopmentExpense | | Research and development | 6 months, 2021-01-01 to 2021-06-30 | $838.5k | us-gaap:ResearchAndDevelopmentExpense | | Operating income | 3 months, 2021-04-01 to 2021-06-30 | −$753.4k | us-gaap:OperatingIncomeLoss | | Operating income | 6 months, 2021-01-01 to 2021-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss | | Net income | 3 months, 2021-04-01 to 2021-06-30 | −$749.7k | us-gaap:NetIncomeLoss | | Net income | 6 months, 2021-01-01 to 2021-06-30 | −$1.3m | us-gaap:NetIncomeLoss | | Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.06 | us-gaap:EarningsPerShareBasicAndDiluted | | Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | −$0.11 | us-gaap:EarningsPerShareBasicAndDiluted | | Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities | | Cash and equivalents | at 2021-06-30 | $29.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue | | Current assets | at 2021-06-30 | $29.8m | us-gaap:AssetsCurrent | | Total assets | at 2021-06-30 | $29.8m | us-gaap:Assets | | Current liabilities | at 2021-06-30 | $652.6k | us-gaap:LiabilitiesCurrent | | Total liabilities | at 2021-06-30 | $652.6k | us-gaap:Liabilities | | Shareholders' equity | at 2021-06-30 | $29.2m | us-gaap:StockholdersEquity | ## Management's discussion and analysis As filed, 13,817 characters. ### Forward-Looking Statements This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In addition, our business and financial performance may be affected by the factors that are discussed under “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 31, 2021. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management. ### Overview We are a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/*neu* protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a completed Phase IIb clinical trial led by MD Anderson Cancer Center, no recurrences were observed in the HER2/*neu* 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months. We are planning to commence a Phase III clinical trial in 2021. To date, we have not generated any revenue and we have incurred net losses. Our net losses were approximately $1.9 million and $3.4 million for the years ended December 31, 2020 and 2019, respectively and $1.3 million and $0.5 million for the six months ended June 30, 2021 and 2020. Our net losses have resulted from costs incurred in developing the drug in our pipeline, planning and preparing for clinical trials and general and administrative activities associated with our operations. We expect to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as we continue to develop our pipeline. Our costs may further increase as we conduct clinical trials and seek regulatory approval for and prepare to commercialize our product candidate. We expect to incur significant expenses to continue to build the infrastructure necessary to support our expanded operations, clinical trials, commercialization, including manufacturing, marketing, sales and distribution functions. We will also experience increased costs associated with operating as a public company. ### Results of Operations for the Three Months Ended June 30, 2021 and 2020 ### Research and Development Expenses Research and development expenses increased by $405,730, or 269%, to $556,534 for the three months ended June 30, 2021 from $150,804 for the three months ended June 30, 2020. The increase was primarily the result of an increase in compensation and manufacturing expenses. ### General and Administrative Expenses General and administrative expenses increased by $137,285, or 230%, to $196,911 for the three months ended June 30, 2021 from $59,626 for the three months ended June 30, 2020. The increase was primarily the result of an increase in costs for raising capital. ### Results of Operations for the Six Months Ended June 30, 2021 and 2020 ### Research and Development Expenses Research and development expenses increased by $537,816, or 179%, to $838,511 for the six months ended June 30, 2021 from $300,695 for the six months ended June 30, 2020. The increase was primarily the result of an increase in compensation and manufacturing expenses. ### General and Administrative Expenses General and administrative expenses increased by $361,164, or 234%, to $515,540 for the six months ended June 30, 2021 from $154,376 for the six months ended June 30, 2020. The increase was primarily the result of an increase in costs for raising capital. ### Liquidity and Capital Resources Since our inception in 2006, we have devoted most of our cash resources to research and development and general and administrative activities. We have not yet achieved commercialization of our product and have a cumulative net loss from our operations. We will continue to incur net losses for the foreseeable future. Our financial statements have been prepared assuming that we will continue as a going concern. We will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through the sale of equity and/or debt securities; however, there is no assurance that we will be successful at raising additional capital in the future. If our plans are not achieved and/or if significant unanticipated events occur, we may have to further modify our business plan, which may require us to raise additional capital. As of June 30, 2021 and December 31, 2020, our principal source of liquidity was our cash, which totaled $29,800,632 and $28,660,375, respectively, and additional loans and accrued unreimbursed expenses from related parties. Historically, our principal sources of cash have included proceeds from the sale of common stock and preferred stock and related party loans. Our principal uses of cash have included cash used in operations. We expect that the principal uses of cash in the future will be for continuing operations, funding of research and development, including our clinical trials, and general working capital requirements. ### Cash Flow Activities for the Six Months Ended June 30, 2021 and 2020 We incurred net losses of $1,346,753 and $455,071 during the six month periods ended June 30, 2021 and 2020, respectively. The increase was primarily the result of an increase in compensation, manufacturing expenses, and costs for raising capital. #### Operating Activities Net cash used in operating activities was $1,132,589 for the six months ended June 30, 2021 and $0 for the six months ended June 30, 2020. #### Investing Activities We did not use or generate cash from investing activities during the six months ended June 30, 2021 and June 30, 2020. #### Financing Activities We used and generated cash netting a total of $2,272,846 from financing activities during the six months ended June 30, 2021 and did not use or generate cash from financing activities during the six months ended June 30, 2020. ### Off-Balance Sheet Arrangements As of June 30, 2021, we did not have any off-balance sheet arrangements as described by Item 303(a)(4) of Regulation S-K. ### Critical Accounting Policies ### Stock-Based Compensation Compensation expense related to warrants and stock granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. ### Recent Accounting Pronouncements We have evaluated the following recent accounting pronouncements through the date the financial statements were issued and filed with the SEC and believe that none of them will have a material effect on our financial statements: In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases: Topic 842” (“ASU 2016-02”), to supersede nearly all existing lease guidance under GAAP. The guidance would require lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets. ASU 2016-02 is effective for the Company in the first quarter of its fiscal year ending December 31, 2019 using a modified retrospective approach with the option to elect certain practical expedients. The Company has no material leases, thus the adoption of ASU 2016-02 will have no material impact on the Company’s financial statements. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts from Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. The amendments in this update affect the guidance in ASU 2014-09. The core principle of the guidance in Topic 606 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 do not change the core principle of the guidance in Topic 606, but instead affect only the narrow aspects noted in Topic 606. Topic 606 became effective for the Company on December 1, 2018. The Company has no revenue, thus the adoption of ASU 2016-12 will have no material impact on the Company’s financial statements. In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. ASU 2018-07 is effective for us for annual periods beginning January 1, 2019. The Company evaluated ASU 2018-07 and determined that the adoption of this new accounting standard did not have a material impact on the Company’s financial statements. ### JOBS Act On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (“Securities Act”) for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (“PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. ## Controls and procedures As filed, 2,870 characters. ### Evaluation of Disclosure Controls and Procedures We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal accounting and financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our principal executive officer and principal accounting and financial officer has concluded that as of June 30, 2021, our disclosure controls and procedures were not effective as of such date as a result of material weaknesses in our internal control over financial reporting due to inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT and financial reporting and record keeping. Under the direction of our principal executive officer and principal financial and accounting officer, we are developing a plan to remediate the material weaknesses. ### Changes in Internal Control over Financial Reporting There was no change in our internal control over financial reporting during our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. ### Limitations on Effectiveness of Controls and Procedures Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. ## Risk factors As filed, 122 characters. There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2020. Filed Aug 13, 2021. Source: SEC EDGAR, the filing index for accession 0001493152-21-019718. Last ingested by Listed: Oct 26, 2026, 16:53 ET. No prices; not investment advice.